Abstract
In this chapter, six medications are selected for hypothetical cost benefit analysis under the type of criteria listed under the Pharmaceutical Benefit Advisory Committee (PBAC) submission guidelines, the standard approach of financial cost benefit analysis and the new3 cost benefit analysis under the normative social choice approach of new3 welfare economics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Copyright information
© 2006 Sardar M.N. Islam and Christine Suet Yee Mak
About this chapter
Cite this chapter
Islam, S.M.N., Mak, C.S.Y. (2006). New3 Cost Benefit Analysis of PBS Medications. In: Normative Health Economics. Palgrave Macmillan, London. https://doi.org/10.1057/9780230289055_6
Download citation
DOI: https://doi.org/10.1057/9780230289055_6
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-54151-5
Online ISBN: 978-0-230-28905-5
eBook Packages: Palgrave Economics & Finance CollectionEconomics and Finance (R0)